Evidence map›Paper›PMID 29737510›Full record

ArticleMedical oncology (Northwood, London, England)2018

Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma.

Pawel Chrom, Maciej Kawecki, Rafal Stec, Lubomir Bodnar, Cezary Szczylik, Anna M Czarnecka

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pawel ChromDepartment of Oncology, Military Institute of Medicine, Szaserow 128, 04-141, Warsaw, Poland.
Maciej KaweckiDepartment of Oncology, Military Institute of Medicine, Szaserow 128, 04-141, Warsaw, Poland.
Rafal StecDepartment of Oncology, Military Institute of Medicine, Szaserow 128, 04-141, Warsaw, Poland.
Lubomir BodnarDepartment of Oncology, Military Institute of Medicine, Szaserow 128, 04-141, Warsaw, Poland.
Cezary SzczylikDepartment of Oncology, Military Institute of Medicine, Szaserow 128, 04-141, Warsaw, Poland.
Anna M CzarneckaDepartment of Oncology, Military Institute of Medicine, Szaserow 128, 04-141, Warsaw, Poland. anna.czarnecka@gmail.com.ORCID http://orcid.org/0000-0002-2107-3810

Funding

Ministerstwo Nauki i Szkolnictwa Wyższego WIM/347
6 · The paper itself

Abstract

In order to facilitate long-term treatment decisions, we aimed to define biomarkers defining the probability of receiving second-line (SL) targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC) based on their characteristics present at first-line TT initiation. We analysed 152 consecutive mRCC patients treated and used multivariable binominal logistic regression to identify factors contributing to the probability of receiving SL TT. Final model was assessed with bias-corrected indices (Nagelkerke's R

Indexed as

Models, StatisticalAdultAgedAged, 80 and overAnilidesAxitinibBiomarkers, TumorBrain NeoplasmsCarcinoma, Renal CellEverolimusFemaleHumansImidazolesIndazolesKidney NeoplasmsLogistic ModelsAnilidesAxitinibBiomarkers, TumorcabozantinibEverolimusImidazolesIndazolesProtein Kinase InhibitorsPyridinesMetastatic renal cell carcinomaProbability calculatorSecond-lineSequential treatmentTyrosine kinase inhibitor

Identifiers

PMID29737510
PMCPMC5940724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.